Shots:
- Merck has reported the P-III (LITESPARK-022) trial data assessing Keytruda (400mg, Q6W, IV) + Welireg (120mg, QD, PO) vs Keytruda + PBO for 1yr. in 1,841 pts with clear cell RCC following nephrectomy
- Trial showed significantly improved disease-free survival (1EP), with OS as 2EP under evaluation; data to be presented in future & shared with global health authorities
- Welireg, an HIF-2α inhibitor, is approved for the treatment of adults with advanced RCC following a PD-1/PD-L1 inhibitor & 1-2 VEGF-TKIs in over 40 countries, incl. the US, Canada, EU, & Japan, based on the P-III (LITESPARK-005) trial
Ref: Merck | Image: Merck | Press Release
Related News:- Merck Reports the US FDA’s Approval of Winrevair (Sotatercept-csrk) to Treat Adults with Pulmonary Arterial Hypertension (PAH)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
